Back Home About Us

IAS 2017: Why Curing Cancer May Be Like Curing HIV -- and May Be As Difficult

For the last few years, a specialist symposium on HIV cure research has preceded the annual International AIDS Society meetings, and this year was no exception, with a 2-day forum at the Curie Institute in Paris before the opening of the 9th IAS Conference on HIV Science (IAS 2017).

alt

Read more:

IDWeek 2017: Long-Acting Monoclonal Antibody Effective Against Multidrug-Resistant HIV

Ibalizumab, a long-acting monoclonal antibody that prevents HIV from entering cells, maintained viral suppression for a year in people with highly resistant HIV and limited treatment options, according to a presentation at the IDWeek 2017 conference last week in San Diego.

alt

Read more:

No New HIV Infections Among Kaiser PrEP Users, But Cascade Shows Missed Opportunities

No new HIV infections have occurred among nearly 5000 people who started Truvada for pre-exposure prophylaxis (PrEP) in the Kaiser Permanente Northern California health system, according to a letter in the July 29 edition of Clinical Infectious Diseases.

alt

Read more:

IDWeek 2017: Single-Tablet Protease Inhibitor Regimen Maintains Viral Suppression for a Year

People who switched from a multi-pill antiretroviral regimen to the first 1-pill, once-daily regimen that includes a protease inhibitor maintained undetectable viral load for a year, according to a report at the IDWeek 2017 conference last week in San Diego.

alt

Read more:

IAS 2017: Experts Agree that Intermittent Oral PrEP Probably Won't Work for Women

Two presenters at the recent International AIDS Society Conference on HIV Science (IAS 2017) in Paris told delegates that both trial results and analysis of drug levels support the idea that event-related or "on demand" pre-exposure prophylaxis (PrEP) might not be sufficiently powerful to prevent HIV infection in women and trans men via vaginal sex.

alt

Read more:

Virally Suppressed People Have "Effectively No Risk" of Transmitting HIV, Says CDC

The US Centers for Disease Control and Prevention (CDC) announced on September 27, National Gay Men’s HIV/AIDS Awareness Day, that HIV diagnoses had fallen among white gay and bisexual men and remained stable among African-American gay men between 2010 and 2014, its last complete year of figures.

alt

Read more:

IAS 2017: Switch from Boosted Protease Inhibitor to Dolutegravir Reduces Lipids in People with HIV

Switching from a boosted protease inhibitor to the integrase inhibitor dolutegravir (Tivicay) was associated with lipid reductions in people with HIV at higher risk of heart disease, according to results of the NEAT 022 study presented at the recent 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris.

alt

Read more:

IAS 2017: Cancer Research May Offer Clues for HIV Cure Research -- and Vice Versa

There is a growing overlap between the fields of cancer and HIV cure research, and approaches that help fight one disease may offer clues about the other. This convergence was the theme of the HIV Cure and Cancer Forum preceding the International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris -- the first time cancer has joined the HIV cure agenda.

alt

Read more:

IAS 2017: Who Are Trans Women Acquiring HIV From?

There is a lot we don't know about trans women's HIV risk, why they are so vulnerable to HIV, and who trans women are acquiring HIV from. A study presented at the recent 9th International AIDS Society Conference on HIV Science (IAS 2017) attempted to answer these questions, but in the process uncovered another mystery: is there a hidden population of heterosexual men who have sex with trans women and who are themselves at high risk of acquiring and transmitting HIV? One thing the study did make clear, however, is that a lot of HIV infections among trans women may be due to injecting drugs rather than sex.

alt

Read more: